

BC Centre for Disease Control

Provincial Health Services Authority

ADVERSE EVENT FOLLOWING IMMUNIZATION (AEFI) CASE REPORT

BCCDC 10000 2024/02/15 Page 1 of 6

INSTRUCTIONS						REPORTING TIPS					
Complete this reporting form for AEFI liste recipient. Reported AEFI should occur afte vaccine or immunization need not be prov	r immunization, and sho en.					Refer to the <u>User Guide</u> for Completion and Submission of AEFI Reports for full					
Public health staff: Report using Panorama (PARIS in VCH).						instructions.					
• Community vaccine providers: Submit the completed form to local public health. Complete all pertinent fields except for Section G & H. Submit the form as indicated <a href="https://example.com/here/bases/base</td><td></td></tr><tr><td>For additional information on reporting cri
immunization, please refer to <u>BC Immunization</u>.</td><td>teria, clinical manageme
ation Manual, Part 5 – Ac</td><td>ent and interpretation of
Iverse Events Following</td><td>AEFIs, as well as implic
Immunization.</td><td>cations for subseq</td><td>uent</td><td></td></tr><tr><td>REPORTER INFORMATION</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Health Authority FHA IHA NHA</td><td>VCH O VIHA</td><td>O PHSA O FNI</td><td>HA</td><td></td><td></td><td></td></tr><tr><td>Setting O Physician office O Hospital</td><td></td><td>ority workplace health</td><td></td><td></td><td></td><td></td></tr><tr><td>Public health Pharmacy</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Last Name</td><td>First Name</td><td><i>,</i>,</td><td>Phone Number (inclu</td><td>uding area code)</td><td>Ext.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Email Address</td><td></td><td></td><td>Fax Number (including</td><td colspan=2>ax Number (including area code)</td><td>Reporter is the health care provider who received and</td></tr><tr><td>Address (including Unit Number, Street Number</td><td>per and Street Name)</td><td></td><td>Province/Territory</td><td>Postal Code</td><td></td><td>reported the AEFI information</td></tr><tr><td>ridaress (including office runiber, street runis</td><td>ci, and street Name,</td><td></td><td>1 Tovinee/Territory</td><td>1 ostal code</td><td></td><td>to the public health unit.</td></tr><tr><td>Branch Office (if applicable)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Signature</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>MD ORN OIMP</td><td>ACT O Pharmacist</td><td>Other (specify)</td><td></td><td></td><td></td></tr><tr><td>Date Reported (YYYY / MM / DD)</td><td>Reported to public he</td><td>alth unit by</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>○ Reporter ○</td><td>Client Other, co</td><td>mplete Section A</td><td></td><td></td><td></td></tr><tr><td>A. SOURCE OF INFORMATION</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Only complete Section A if " is="" other"="" selecte<="" td=""><td></td><td>c health unit by"</td><td>DI N 1 (* 1</td><td>1. 1.</td><td>F .</td><td></td>							c health unit by"	DI N 1 (* 1	1. 1.	F .	
Last Name	First Name		Phone Number (inclu	uding area code)	EXT.						
Email Address		Relationship to Client				Source of information can be the same as reporter, the					
Email Address		helationship to client				client, or a secondary source					
Address (including Unit Number, Street Numb	per and Street Name)		Province/Territory	Postal Code		such as a parent/guardian.					
, radices (metading official metadine)	ci, and street value,		Trovince, remiery	1 ostar code							
B. CLIENT INFORMATION											
Last Name	First Name		Middle Name(s)								
Date of Birth (YYYY / MM / DD) Gender			Health Card Number	(PHN)							
◯ Mai	e O Female O Tran	sgender O Unknown	n								
Phone Number(s) (include area code, and extended	ension if applicable)	Alternate Name(s) (if a	pplicable)			A L L L L DA DIG					
						Adverse event ID and PARIS ID are system generated IDs,					
Address (including Unit Number, Street Number	er, and Street Name)		Province/Territory	Postal Code		not reportable to local public					
						health.					
Country of Residence (if not Canada)						Enter IMPACT Local Inventory Number if the report was					
	1		T			received from IMPACT;					
ADVERSE EVENT ID	IMPACT LIN		PARIS ID			otherwise leave it blank.					
D. C. W. Dh. C. C. C.	 										
Patient's Physician (or Primary Co	First Name		Phone Number (inclu	ıding area codo)	Fyt						
Last Name	THEFT		Thore Number (IIICI)	ading area code)	LAL.						
Address (including Unit Number, Street Number,	per, and Street Name)		Province/Territory	Postal Code							

C. IMMUNIZATION	ON DATA								
Date Vaccine Administered^	Immunizing Agent	Trade Name	Manufacturer	Lot Number	Dose Number	Dosage/ Unit	Route	Site	
(YYYY / MM / DD)	Agent			Number	Number	Offic			
									^Date of vaccine administered should be the same for all vaccines associated with a
									single AEFI report.
Name of Health Care	Provider who admii	nistered the vaccing	2		Phone Nu	ımber (includ	ing area cod	e) Ext.	
			-				9 a. ca coa		
Address					Province/	Territory	Postal Code		
D. INFORMATIO	N AT TIME OF	IMMUNIZATIO	ON AND AEFI (ONSET					
Breastfeeding at time	of immunization ‡		Pregna	ant at time of	immunizatio	n			‡Refers to whether the adult
O No O Unk	known O Yes	i	O N	lo O U	nknown	O Yes			for whom the AEFI is being
Did an AEFI follow a p	revious dose of any	of the above imm	unizing agents liste	d in section (?				reported was lactating/ breastfeeding a child at the
O No O No	Prior Doses C	Unknown (Yes (if Yes, provid	e details belo	ow)				time of immunization.
Comments									
Did this AEFI follow an incorrect immunization?									
○ No ○ Unknown ○ Yes (if Yes, choose all that apply and provide details below)									
☐ Given outside the recommended age limits ☐ Product expired ☐ Dose exceeded that recommended for age ☐ Wrong vaccine given ☐ Incorrect route ☐ Other, specify									
	ine given	Incorrect route	Uther, specif	У					
Comments									
Medical history (up to	time of AFFI oncot) Chack all that ann	ly and provide deta	ile bolow					
Concomitant me			cal conditions/allerg	_	Acute illne	cc/iniury			
Conconitant me	edication(s)		edical condition(s)	gies [_	at time of rep	ort		
Comments		No known in	edical condition(3)		OTIKITOWITE	at time of rep	011		
Comments									
E. AEFI DETAILS									
Complete all sections		each event check a	all signs/symptoms	that apply. Ite	em(s) with as	terisk (*) shou	ıld be diagno	sed by	
a physician. If not, pro details and test result		mation to support	the selected item(s). Use Section	n I for additio	nal informati	on including	clinical	
E1. Local Reacti									
Onset - from immuniz			Duration - from 1s		_	•	_		Calastanus line le la la
Min. or	Hrs. or	Days	Min.	or	Hrs. or	Day	rs Unre	solved	Select applicable local reaction(s) before selecting
Infected abscess			_			tches joint-to	-joint	Rash	symptoms/signs on the
Pain or redness of	_				mphadenitis*				following page.
Pain or redness or swelling persisting for 10 days or more Other, specify: For tips on where to report rash see Section L.							For tips on where to report		
									.as.i see seedon L
Local reaction section	continues on the new	rt nane							1

ADVERSE EVENT FOLLOWING IMMUNIZATION (AEFI) CASE REPORT

BCCDC 10000 2024/02/15 Page 3 of 6

E. AEFI DETA	ILS continued				
		ar Injection Site ϵ			
If an injection sit	e reaction is repo	rted on page 2, check a	ll symptoms/signs that a	apply and provide details below.	Only select local signs/
Swelling	Pain Ter	nderness Erythen	na Warmth	Induration	symptoms if one or more local reaction is reported.
		reactioncm			Specify Microbial results in
Palpable fluc			aging technique (e.g., MF		comment box.
Spontaneous	s/surgical drainage	Microbial results	(specify) Lymphan	gitic streaking Regional lymphadenopathy	
Comments					
E2 Anaphyla	vic and Other	· Allergic Events			
			Duration - from 1st sympt	tom/sign to resolution of all symptoms/signs	
		or Days	•	Hrs. orDays Unresolved	
Anaphylaxis	Oculo-Res	piratory Syndrome (ORS	Other allergic	events	
Epinephrine	administered				
For the event ind	licated above, sele	ect all symptoms/signs	that apply and provide	details in comments below.	Choose allergic signs/
Skin/mucosal	Generalized	At injection site	☐ Non-injection site	Urticaria Erythema	symptoms only if an allergic
		Pruritus	Prickle sensation	Rash	event (anaphylaxis, ORS, or
	Localized	At injection site	Non-injection site	Urticaria Erythema	Other allergic events) is being reported.
		Pruritus	Prickle sensation	Rash	If a client only reports GI
				_	symptoms that are not
	L Eyes	Red bilateral	Red unilateral	L Itchy	allergic in nature, report in
	Angioedema		Throat	Uvula Larynx Lip	the appropriate event in the "Other event" section.
		Eyelids	Face	Limbs Reported sensation of swelling	For tips on where to report
		☐ Visible swelling	Other, specify:		rash see Section L.
Cardiovascular	Measured hyp	<u> </u>	central pulse volume	Capillary refill time >3 sec	
	Tachycardia	\ \	or loss of consciousness		
Respiratory	Sneezing	Rhinorrhea	Hoarse voice	Sensation of throat closure Stridor	
	Dry cough	☐ Tachypnea	Wheezing	Increased use of accessory muscles	
	Grunting	Cyanosis	Sore throat	Indrawing/retractions	
	Difficulty swa	llowing	Chest tightness	☐ Difficulty breathing	
Gastrointestinal	Diarrhea	Abdominal pain	Nausea	Vomiting	
Laboratory	Mast cell tryp	tase elevation > upper n	ormal limit		
Comments		tuse elevations append	Officer militie		
Comments					

Inform the person on whom this information is being collected that we are collecting your personal information under the authority of sections 26 (c) and (e) of the BC Freedom of Information and Protection of Privacy Act ("FIPPA"). The information you provide to us will be used for public health surveillance purposes. Questions regarding the collection of your personal information or requests for records may be directed to the Information Access Privacy office that supports BCCDC at privacyandfoi@phsa.ca or 604.707.5833.

E. AEFI DETAILS continued		
E3. Neurologic Event		
, , ,	- from 1st symptom/sign to resolution of all symptoms/signs	
Min. or Hrs. or Days	Min. or Hrs. or Days Unresolved	
Seizure(s) (check all that apply)		
Febrile Afebrile Unknown type		
Focal/Partial		
or		Item(s) with asterisk (*) should
Generalized, specify: Tonic Clonic	Tonic-clonic Atonic Myoclonic Absence	be diagnosed by a physician.
Witnessed by health care professional: Yes	○ No ○ Unknown	Select the appropriate neurological event, before
Sudden loss of consciousness: Yes	○ No ○ Unknown	choosing corresponding
		descriptors.
	e Alebriie Onknown type	Report "ADEM or SSPE" as "Other neurological diagnosis,
Anaesthesia/Paraesthesia (check all that apply)		specify".
Generalized OR Localized		Report Vaccine-associated
Numbness Tingling Burning For	mication Other, specify:	Paralytic Poliomyelitis as
Meningitis* Encephalopathy/Encephalitis* Guilla	in-Barre Syndrome (GBS)* Bell's Palsy*	"Other paralysis".
Myelitis/Transverse myelitis* Other paralysis*	Other neurological diagnosis*, specify:	
Subacute sclerosing panencephalitis		
For any neurological event indicated above, check all that apply	and provide details in comments below	_
Depressed/altered level of consciousness/Lethargy/ P	•	
Focal or multifocal neurologic sign(s) Fever		
EMG abnormality Neuroimaging abnormal	, ,	
Comments		
E4. Other Defined Events of Interest		
	- from 1st symptom/sign to resolution of all symptoms/signs	
	- from 1st symptom/sign to resolution of all symptoms/signsMin or Hrs or Days Unresolved	
Onset - from immunization to onset of 1st symptom/sign	, , , , , , , , , , , , , , , , , , , ,	
Onset - from immunization to onset of 1st symptom/sign	Min. or Days Unresolved Kawasaki disease*	
Onset - from immunization to onset of 1st symptom/sign	Min. or Hrs. or Days Unresolved Kawasaki disease* Thrombocytopenia*	
Onset - from immunization to onset of 1st symptom/sign Min. or Hrs. or Days Hypotonic-Hyporesponsive Episode* (age <2 years) Limpness Pallor/cyanosis	Min. or Hrs. or Days Unresolved Kawasaki disease*	
Onset - from immunization to onset of 1st symptom/sign Min. orHrs. orDays Hypotonic-Hyporesponsive Episode* (age <2 years) LimpnessPallor/cyanosis Reduced responsiveness/unresponsiveness Persistent crying (continuous and unaltered crying for ≥3 hours)	Min. or Hrs. or Days Unresolved Kawasaki disease*	
Onset - from immunization to onset of 1st symptom/sign Min. orHrs. orDays Hypotonic-Hyporesponsive Episode* (age <2 years) Limpness Pallor/cyanosis Reduced responsiveness/unresponsiveness	Min. or Hrs. or Days Unresolved Kawasaki disease*	Item(s) with asterisk (*) should
Onset - from immunization to onset of 1st symptom/sign Min. or Hrs. or Days Hypotonic-Hyporesponsive Episode* (age <2 years) Limpness Pallor/cyanosis Reduced responsiveness/unresponsiveness Persistent crying (continuous and unaltered crying for ≥3 hours) Rash (Refer to Immunization Manual, Part 5 for reporting criteria.	Min. or Hrs. or Days Unresolved Kawasaki disease* Thrombocytopenia* Platelet count <150×109/L Petechial rash Other clinical evidence of bleeding Thrombosis* Thromboembolism*	Item(s) with asterisk (*) should be diagnosed by a physician.
Onset - from immunization to onset of 1st symptom/sign Min. orHrs. orDays Hypotonic-Hyporesponsive Episode* (age <2 years) LimpnessPallor/cyanosis Reduced responsiveness/unresponsiveness Persistent crying (continuous and unaltered crying for ≥3 hours) Rash (Refer to Immunization Manual, Part 5 for reporting criteria. For rash at injection site or rash in allergic reaction, use sections above.)	Min. or Hrs. or Days Unresolved Kawasaki disease*	
Onset - from immunization to onset of 1st symptom/sign Min. or Hrs. or Days Hypotonic-Hyporesponsive Episode* (age <2 years) Limpness	Min. or Hrs. or Days Unresolved Kawasaki disease* Thrombocytopenia* Platelet count <150×109/L Petechial rash Other clinical evidence of bleeding Thrombosis* Thromboembolism* Fever ≥38°C (Report only if fever occurs in conjunction with reportable event. For a neurological event use section above.)	
Onset - from immunization to onset of 1st symptom/sign Min. orHrs. orDays Hypotonic-Hyporesponsive Episode* (age <2 years) LimpnessPallor/cyanosis Reduced responsiveness/unresponsiveness Persistent crying (continuous and unaltered crying for ≥3 hours) Rash (Refer to Immunization Manual, Part 5 for reporting criteria. For rash at injection site or rash in allergic reaction, use sections above.) GeneralizedLocalized at non-injection site Intussusception*	Min. or Hrs. or Days Unresolved Kawasaki disease*	
Onset - from immunization to onset of 1st symptom/sign Min. orHrs. orDays Hypotonic-Hyporesponsive Episode* (age <2 years) LimpnessPallor/cyanosis Reduced responsiveness/unresponsiveness Persistent crying (continuous and unaltered crying for ≥3 hours) Rash (Refer to Immunization Manual, Part 5 for reporting criteria. For rash at injection site or rash in allergic reaction, use sections above.) GeneralizedLocalized at non-injection site Intussusception* Hematochezia*	Min. or Hrs. or Days Unresolved Kawasaki disease* Thrombocytopenia* Platelet count <150×109/L Petechial rash Other clinical evidence of bleeding Thrombosis* Thromboembolism* Fever ≥38°C (Report only if fever occurs in conjunction with reportable event. For a neurological event use section above.) Syncope with injury Severe vomiting	
Onset - from immunization to onset of 1st symptom/sign Min. or Hrs. or Days Hypotonic-Hyporesponsive Episode* (age <2 years) Limpness	Min. or Hrs. or Days Unresolved Kawasaki disease*	
Onset - from immunization to onset of 1st symptom/sign Min. or Hrs. or Days Hypotonic-Hyporesponsive Episode* (age <2 years) Limpness	Min. or Hrs. or Days Unresolved Kawasaki disease* Thrombocytopenia* Platelet count <150×109/L Petechial rash Other clinical evidence of bleeding Thrombosis* Thromboembolism* Fever ≥38°C (Report only if fever occurs in conjunction with reportable event. For a neurological event use section above.) Syncope with injury Severe vomiting	
Onset - from immunization to onset of 1st symptom/sign Min. or Hrs. or Days Hypotonic-Hyporesponsive Episode* (age <2 years) Limpness Pallor/cyanosis Reduced responsiveness/unresponsiveness Persistent crying (continuous and unaltered crying for ≥3 hours) Rash (Refer to Immunization Manual, Part 5 for reporting criteria. For rash at injection site or rash in allergic reaction, use sections above.) Generalized Localized at non-injection site Intussusception* Hematochezia* Arthritis* Joint redness Joint warm to touch Joint swelling Inflammatory changes in synovial fluid	Min. or Hrs. or Days Unresolved Kawasaki disease*	
Onset - from immunization to onset of 1st symptom/sign Duration	Min. or Hrs. or Days Unresolved Kawasaki disease*	
Onset - from immunization to onset of 1st symptom/sign Duration	Min. or Hrs. or Days Unresolved Kawasaki disease*	
Onset - from immunization to onset of 1st symptom/sign Min. or Hrs. or Days Hypotonic-Hyporesponsive Episode* (age <2 years) Limpness	Min. or Hrs. or Days Unresolved Kawasaki disease*	
Onset - from immunization to onset of 1st symptom/sign Min. or Hrs. or Days Hypotonic-Hyporesponsive Episode* (age <2 years) Limpness	Min. or Hrs. or Days Unresolved Kawasaki disease*	
Onset - from immunization to onset of 1st symptom/sign Min. or Hrs. or Days Hypotonic-Hyporesponsive Episode* (age <2 years) Limpness	Min. or Hrs. or Days Unresolved Kawasaki disease*	
Onset - from immunization to onset of 1st symptom/sign Min. or Hrs. or Days Hypotonic-Hyporesponsive Episode* (age <2 years) Limpness	Min. or Hrs. or Days Unresolved Kawasaki disease*	
Onset - from immunization to onset of 1st symptom/sign Min. or Hrs. or Days Hypotonic-Hyporesponsive Episode* (age <2 years) Limpness	Min. or Hrs. or Days Unresolved Kawasaki disease*	

	T OF AEFI, OUTCO pact of AEFI (Choose on			CARE OBTAINED		
l _	t interfere with daily acti	_	~	did not prevent daily activ	ities Prevented daily activities	
Outcome at	t time of report (Choose	e one of th	e following):			YYYY / MM / DD
O Perma	nent disability/incapacit	y O N	ot yet recovered	Fully recovered	Unknown Death (specify date):	
	el of care obtained (Ch essment in an emerger			ormal admission to hosp	ital as "Emergency Visit".)	
○ Emerg	ency visit O Non-	urgent visi	t O Telepho	ne advice from a health pi	rofessional O None O Unknow	١
O Admitt	ed to Hospital (days)	Resulted	d in prolongation of existir	ng hospitalization (by days)	
Hospital Na	ame				Hospital Admission Date (YYYY / MM / DD) Hospital Discharge Date (YYYY / MM / DD)
Treatment	received (If Yes, provide	details of t	reatment, includir	ng self-treatment)		
○ No	O Unknown) Yes				
	RTABILITY – FOR P					
	ent reported meet repor	-			started in the public health information sys	tom
O les (el				report was previously s	tarted in the public health information sys	tem,
H. PUBLI	C HEALTH RECOM	IMEND <i>A</i>	ATIONS – <i>FOR</i>	PUBLIC HEALTH US	SE ONLY (Provide comments; us	Section I if extra space needed)
☐ No char	nge to immunization sch	edule		Controlled setting for next	immunization (specify)	
Determi	ine protective antibody I	level (speci	ify)	Active follow up for AEFI re	currence after next vaccine (specify)	
l	ner immunizations (speci	ify)		Other (specify)		
Expert r	eferral (specify)			No recommendations (spe	cify)	
Comments						
Name of MC	OH or Designate making	the recom	mendation	Professional Status		
				○ мон/мно ○ г	MD Other (specify)	
Phone (inclu	uding area code)		Date (YYYY / MM /	DD)	Signature	
Send a copy	<u> </u>					
☐ BCCDC			Other (specify)			
	EMENTARY INFOR			ovida dataile of any invar	stigation or treatment for the recorded <i>l</i>	EEL Dravida sufficient information to
	e selected item(s). App	•	-		sugation of treatment for the recorded h	teri. Provide sufficient information to
Section	Comments					
I	İ					

J. ADVERSE EVENTS FOLLOWING IMMUNIZATION – REPORTABILITY

Reportable: Any event listed in the BC Immunization Manual, Part 5 - Section 6. Summary of Reporting Criteria in a vaccine recipient which follows immunization that cannot be clearly attributed to other causes. A causal relationship with the administration of the vaccine does not need to be proven.

Does not meet reporting criteria: Any event which follows immunization that has been clearly attributed to other causes **OR** does not meet reporting criteria (e.g., not serious such as mild vomiting or diarrhea, temporal relationship incompatible with association with vaccine receipt).

K. ADVERSE EVENTS FOLLOWING IMMUNIZATION – TEMPORAL CRITERIA

The length of time between vaccine administration and onset of symptoms is an important consideration in causality assessment. Temporal criteria guidelines in this table are generally agreed upon approximate timelines.

Reaction Type	Adverse Event Following Immunization	Temporal Criteria			
кеасион туре	Adverse Event Following immunization	Inactivated Vaccines	Live Attenuated Vaccines		
	Infected Abscess	0-7 days			
	Sterile Abscess	0-7 days			
Local Reactions at Injection Site	Cellulitis	0-7 days			
injection site	Nodule	0-7 days			
	Pain or Redness or Swelling	0-48 hours			
	Adenopathy/Lymphadenopathy	0-7 days	MMR: 5 - 30 days; Varicella: 5 - 42 days		
	Fever	Timing in conjunction w	ith other reportable adverse events		
	Hypotonic-Hyporesponsive Episode (HHE)		0-48 hours		
c	Parotitis	Not applicable	MMR: 5-30 days		
Systemic Reactions	Orchitis	Not applicable	MMR: 5-30 days		
	Rash	0-7 days	MMR: 0 - 30 days; Varicella: 0 - 42 days		
	Screaming/Persistent crying		0-72 hours		
	Severe Vomiting/Diarrhea	0-72 hours	0-72 hours; 0-7days for Rotavirus vaccines		
	Anaphylaxis	0-24 hours			
Allergic Reactions	Oculo-respiratory Syndrome (ORS)	0-24 hours			
	Other Allergic Reactions	0-48 hours			
	Anaesthesia/Paraesthesia	0-15 days	MMR: 0 - 30 days; Varicella: 0 - 42 days		
	Bell's Palsy	1	0-3 months		
	Convulsion/Seizure	0-72 hours	MMR: 5 - 30 days; Varicella: 5 - 42 days		
Neurological Events	Encephalopathy/Encephalitis, Myelitis/Transverse myelitis or Acute Disseminated Encephalomyelitis (ADEM)	0-42 days	MMR: 5 - 30 days; Varicella: 5 - 42 days		
	Guillain-Barré syndrome (GBS)	0-56 days			
	Meningitis	Not applicable	MMR: 5 - 30 days; Varicella: 5 - 42 days		
	Paralysis	Not applicable	OPV: 5 - 30 days; Varicella: 5 - 42 days		
	Arthritis	0-30 days	MMR: 5 - 30 days; Varicella: 5 - 42 days		
	Kawasaki disease	0-15 days			
Other Events of	Intussusception or Hematochezia	Not applicable	Rotavirus: 0 - 42 days		
	Thrombocytopenia	0-30 days			
	Thrombosis/Thromboembolism	0-37 days			
	Syncope with injury	0-30 minutes			
	Myocarditis and/or Pericarditis	0-21 days			
	Other severe or unusual	A temporal association to immunization and for which there is no other known cause and not covered under the other categories			

L. RASH REPORTING TIPS

Localized rash at the injection site: Local reaction at or near injection site > Rash > Select details that apply > Specify any additional details in local comments.

Localized allergic rash: Anaphylaxis and other allergic events > Skin/mucosal > Localized > Select "At injection site" or "Non-injection site" > Select "Rash" > Specify details in allergic comments.

Generalized allergic rash: Anaphylaxis and other allergic events > Skin/mucosal > Generalized > Select "At injection site" and/or "Non-injection site" > Select "Rash" > Specify details in allergic comments.

Generalized rash: Other defined events of interest > Rash > Generalized > Specify details in other comments.

Localized rash at non-injection site: Other defined events of interest > Rash > Localized at non-injection site > Specify details in other comments.